Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
暂无分享,去创建一个
[1] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.
[2] D. Neuberg,et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.
[3] J. Soulier,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[4] J. Cortes,et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. , 2016 .
[5] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[6] A. Bartolucci,et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Kolitz,et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. , 2012, Leukemia research.
[8] Yi Ning,et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.
[9] C. Volteau,et al. Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study , 2011 .
[10] M. Andreeff,et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. , 1989, Leukemia.
[11] J. Lamba. Genetic factors influencing cytarabine therapy. , 2009, Pharmacogenomics.
[12] M. Vignetti,et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] O. Abdel-Wahab,et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. , 2016, Blood.
[14] J. Marin,et al. Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. , 2016, Blood reviews.
[15] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] R. Hills,et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis , 2009, Leukemia.
[17] P. Sonneveld,et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] U. Dührsen,et al. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] F. Mandelli,et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. , 1991, European journal of cancer.
[20] R. Hills,et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. , 2014, Blood.
[21] Y. Min,et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. , 2011, Blood.
[22] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[23] Francine E. Garrett-Bakelman,et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia , 2016, Nature Medicine.
[24] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[25] E. Estey,et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. , 1996, Leukemia.
[26] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[27] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[28] J. Bourhis,et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] C. Craddock,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[31] J. Radich,et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.
[32] E. Estey,et al. Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia , 2014, Leukemia.
[33] W. Jędrzejczak,et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study , 2004, Leukemia.
[34] W. Hiddemann,et al. Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study , 2016 .
[35] Ling Zhang,et al. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications , 2017, Leukemia & lymphoma.
[36] Michael S Mathisen,et al. Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.
[37] Thomas J. Hudson,et al. Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.
[38] E. Estey,et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. , 1996, Blood.
[39] N. Schmitz,et al. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia , 2016, Leukemia.
[40] H. Einsele,et al. TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation , 2016, British journal of haematology.
[41] J. Cortes,et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. , 2014, Blood.
[42] G. Rosner,et al. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia , 2015, Haematologica.
[43] B. Vick,et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia , 2016, Nature Medicine.
[44] M. Konopleva,et al. Role of Microenvironment in Resistance to Therapy in AML , 2015, Current Hematologic Malignancy Reports.
[45] R. Hills,et al. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. , 2016, Blood.
[46] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.
[47] P. Desai,et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. , 1990, Leukemia.
[48] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[49] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[50] J. Yates,et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. , 1973, Cancer chemotherapy reports.
[51] I. Weissman,et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.
[52] H. Kantarjian,et al. Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML , 2015, Cancer.
[53] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[54] A. Hagemeijer,et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] S. Fröhling,et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.
[57] E. Estey,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.
[58] C. Mason,et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. , 2015, Cancer cell.
[59] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[60] Inigo Martincorena,et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach , 2017, Nature Genetics.
[61] Je-Jung Lee,et al. Cellular immunotherapy as a beacon of hope for hematological malignancies , 2015, Blood research.
[62] J. Beyene,et al. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta‐analysis , 2013, British journal of haematology.
[63] H. Uno,et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. , 2010, Blood.
[64] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[65] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[66] B. George,et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. , 2015, Pharmacogenomics.
[67] M. Caligiuri,et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] Shuangnian Xu,et al. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. , 2015, The Cochrane database of systematic reviews.
[69] F. Mandelli,et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia , 1991 .
[70] B. Ko,et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution , 2015, Blood Cancer Journal.
[71] J. Radich,et al. SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) , 2016 .
[72] Lawrence Mayer,et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.
[73] M. Béné,et al. Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia , 2014, Leukemia.
[74] Christopher A. Miller,et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.
[75] H. Kantarjian,et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.
[76] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.
[77] G. Garcia-Manero,et al. Decitabine in TP53-Mutated AML. , 2017, The New England journal of medicine.
[78] J. Panetta,et al. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia , 2016, Cancer Chemotherapy and Pharmacology.
[79] P. Venugopal,et al. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] P. Sonneveld,et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. , 2005, Blood.
[81] Christopher A. Miller,et al. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. , 2015, JAMA.
[82] D. Neuberg,et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.
[83] B. Christensen,et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. , 1991, Leukemia.
[84] J. Matthews,et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.
[85] D. Neuberg. Reprise: gemtuzumab ozogamicin for older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[87] C. Bloomfield,et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. , 1981, Blood.
[88] T. Naoe,et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.
[89] M. Bally,et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.
[90] A. Krämer,et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] C. Schiffer,et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. , 1991, Blood.
[92] C. Mason,et al. Genetic and epigenetic heterogeneity in acute myeloid leukemia. , 2016, Current opinion in genetics & development.
[93] J. Gabrilove,et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. , 1991, Blood.
[94] C. Clarke,et al. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis , 2015, Cancer.
[95] W. Wiktor-Jedrzejczak,et al. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial , 2017, American journal of hematology.
[96] C. Bloomfield,et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.
[97] F. Appelbaum,et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. , 2002, Blood.
[98] B. Esterni,et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia , 2007, Cancer.
[99] H. Preisler,et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. , 1987, Blood.
[100] T. Haferlach,et al. MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations , 2016, Leukemia.
[101] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.
[102] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[103] E. Beutler. Cladribine (2-chlorodeoxyadenosine) , 1992, The Lancet.
[104] E. Fisher,et al. Income and Cancer Overdiagnosis - When Too Much Care Is Harmful. , 2017, The New England journal of medicine.
[105] Francine E. Garrett-Bakelman,et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling , 2016, Nature Medicine.
[106] M. Grever,et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.
[107] R. Lynch,et al. Chemotherapy options for previously untreated acute myeloid leukemia , 2015, Expert opinion on pharmacotherapy.
[108] W. Jędrzejczak,et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[110] T. Haferlach,et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases , 2017, Leukemia.
[111] V. Raina,et al. Comparison of 2 doses of daunorubicin(45mg/m2 vs 60mg/m2) in induction therapy of patients of de novo acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] M. Baccarani,et al. Liposomal daunorubicin versus standard daunorubicin: long term follow‐up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia , 2008, British journal of haematology.
[113] J. Kolitz,et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] V. Rotter,et al. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. , 2017, Blood.
[115] H. Einsele,et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. , 2015, The Lancet. Oncology.